Page last updated: 2024-08-21

adamantane and triazoles

adamantane has been researched along with triazoles in 140 studies

Research

Studies (140)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (0.71)	18.7374
1990's	2 (1.43)	18.2507
2000's	52 (37.14)	29.6817
2010's	78 (55.71)	24.3611
2020's	7 (5.00)	2.80

Authors

Authors	Studies
Kreutzberger, A; Schröders, HH	1
el-Emam, AA; Ibrahim, TM	1
Karasawa, A; Kishibayashi, N; Suzuki, M; Tomaru, A	1
De Clercq, E; Kritsanida, M; Marakos, P; Mouroutsou, A; Pannecouque, C; Papakonstantinou-Garoufalias, S; Pouli, N; Witvrouw, M	1
Aster, SD; Balkovec, JM; Brown, K; Carbin, L; Graham, DW; Hermanowski-Vosatka, A; LeGrand, CB; Mundt, SS; Olson, S; Robbins, MA; Schaeffer, JM; Slossberg, LH; Szymonifka, MJ; Thieringer, R; Wright, SD	1
Erlich, R	1
Balkovec, JM; Chen, HY; Cheng, K; Hermanowski-Vosatka, A; Hernandez, M; Koo, GC; Le Grand, CB; Li, Z; Metzger, JM; Mundt, SS; Noonan, H; Nunes, CN; Olson, SH; Pikounis, B; Ren, N; Robertson, N; Schaeffer, JM; Shah, K; Springer, MS; Strack, AM; Strowski, M; Thieringer, R; Wright, SD; Wu, K; Wu, T; Xiao, J; Zhang, BB	1
Kondo, Y; Mitsukura, K; Nagasawa, T; Yoshida, T	1
Heinzl, S	1
Jago, C	1
Dondoni, A; Marra, A	1
Barnett, A	1
Drucker, DJ; Nauck, MA	1
Bailey, CJ; Flatt, PR; Green, BD	2
Ahrén, B	5
Winkler, G	1
Pratley, RE; Salsali, A	1
Bloomgarden, ZT; Inzucchi, SE	1
Klein, HH; Meier, JJ; Schmidt, WE	1
Scheen, AJ	5
Amori, RE; Lau, J; Pittas, AG	1
Jennings, HR; Langley, AK; Suffoletta, TJ	1
Bartberger, MD; Castro, VM; Chen, M; Emery, M; Fotsch, C; Gustafsson, S; Hale, C; Hickman, D; Homan, E; Johansson, L; Jordan, SR; Komorowski, R; Li, A; Matsumoto, G; McRae, K; Moniz, G; Orihuela, C; Palm, G; Veniant, M; Wang, M; Williams, M; Zhang, J	1
Bandeira-Echtler, E; Bergerhoff, K; Lerch, CL; Richter, B	1
Mikhail, N	2
Deacon, CF; Holst, JJ; Krarup, T; Madsbad, S	1
Pei, Z	1
Gadsby, R	1
Doupis, J; Veves, A	1
De Meester, I; Lambeir, AM; Scharpé, S	1
Davidson, JA; Gross, JL; Parente, EB	1
Faust, M; Matthes, J	1
Fonseca, VA; John-Kalarickal, J; Wani, JH	1
Bosi, E; Lucotti, P; Monti, L; Piatti, PM; Setola, E	1
Seissler, J	1
Bandeira-Echtler, E; Bergerhoff, K; Lerch, C; Richter, B	1
Gupta, R; Pal, M; Parsa, KV; Singh, SK; Tokala, RK; Walunj, SS	1
Siddiqui, NI	1
Argyrakopoulou, G; Doupis, J	1
Nicolucci, A; Rossi, MC	1
Gallwitz, B	2
Miuchi, M; Miyagawa, J; Nanba, M	1
Gallwitz, B; Thornberry, NA	1
Curtiss, FR; Fairman, KA	1
Bode, BW	1
Barnett, AH; Palalau, AI; Piya, MK; Tahrani, AA	1
Freeman, JS	1
Schubert-Zsilavecz, M; Steinhilber, D; Zettl, H	1
Bilo, HJ; Goudswaard, AN; Houweling, ST; Kleefstra, N; Kooy, A; van Hateren, KJ; Verhoeven, S	1
Cefalu, WT	1
Guerci, B; Halter, C	1
Unger, J	1
Kuritzky, L	1
Fakhoury, WK; Lereun, C; Wright, D	1
Svec, F	1
Clar, C; Cummins, E; Marien, M; Philip, S; Richter, B; Royle, P; Waugh, N	1
Gerich, J	1
Garber, AJ	1
Campbell, RK; Cobble, ME; Reid, TS; Shomali, ME	5
Charpentier, G; Gause-Nilsson, I; Hellqvist, A; Ostgren, CJ; Scheen, AJ	1
Boudes, P; Viereck, C	1
Jellinger, PS	1
Bourdel-Marchasson, I; Dejager, S; Schweizer, A	1
Avogaro, A; de Kreutzenberg, SV; Fadini, GP; Gjini, R	1
Fan, L; Gruenberger, JB; Kantor, E; Signorovitch, JE; Swallow, E; Wu, EQ	1
Gibbs, JP; Greene, RJ; Greg Slatter, J; Tu, H	1
Jermendy, G	2
Gerrald, KR; Jonas, DE; Runge, T; Van Scoyoc, E; Wines, RC	1
Barbee, T; Correa, I; Fredrickson, J; Gibbs, JP; Gibbs, MA; Lin, SL; Smith, B	1
Edwards, KL; Irons, BK; Stapleton, MR; Weis, JM	1
Dorso, C; Hamann, L; Harstad, E; Kirby, MS; Kopcho, L; Langish, R; Locke, G; Marcinkeviciene, J; Shipkova, P; Wang, A	1
Cheetham, S; Francis, J; Kirby, M; Poucher, SM; Vickers, SP; Zinker, B	1
Barbieri, M; Marfella, R; Paolisso, G; Rizzo, MR	2
Ishikawa, M; Yamada, Y	1
Colette, C; Comenducci, A; Dejager, S; Monnier, L; Vallée, D	1
Colette, C; Dejager, S; Guerci, B; Huet, D; Monnier, L; Petit, C; Quéré, S; Raccah, D; Serusclat, P; Valensi, P	1
Ando, K; Irako, T; Nishimura, R; Sakamoto, M; Tsujino, D; Utsunomiya, K	1
Abe, Y; Anabuki, J; Fukuda-Tsuru, S; Ishii, S; Yoshida, K	1
Falck, JR; Morisseau, C; Mustafa, SJ; Nayeem, MA; Pradhan, I; Zeldin, DC	1
Devries, JH	1
Bakris, GL; Flynn, C	1
Barbieri, M; Boccardi, V; Esposito, A; Marfella, R; Pansini, A; Paolisso, G; Rizzo, MR	1
Codd, R; Crouch, PJ; Ganio, G; Liddell, JR; Liu, J; Mok, SS; Obando, D; Volitakis, I; White, AR	1
Blétry, O; Bouilloud, F; Crickx, E; Kahn, JE; Le Beller, C; Marroun, I; Schoindre, Y; Veyrie, C	1
Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Pintana, H	2
Akahoshi, F; Ishii, S; Kadowaki, T; Kishida, H; Miyaguchi, I; Nabeno, M; Tanaka, Y	1
Cohen, D	1
Assmann, G; Brenner, C; Brunner, S; David, R; Franz, WM; Gross, L; Mueller-Hoecker, J; Nathan, P; Steinbeck, G; Theiss, HD; Vallaster, M; Vogeser, M	1
Charbonnel, B; Dejager, S; Schweizer, A	1
Batra, M; Chaudhuri, A; Dandona, P; Kuhadiya, N; Makdissi, A	1
Bae, JH; Cho, YM; Jung, HS; Kim, SY; Kim, YG; Oh, TJ; Park, KS	1
Al-Omar, MA; Al-Tamimi, AM; Alrashood, KA; El-Emam, AA; Habib, EE	1
Begum, SS; Hausenloy, DJ; Mocanu, MM; Riksen, N; Theodorou, L; Whittington, HJ; Wynne, AM; Yellon, DM	1
Anz, D; Bourquin, C; Endres, S; Haubner, S; Kruger, S; Rapp, M	1
Goto, C; Mizui, T; Ohta, H; Tachi, T; Teramachi, H; Toyoshima, M; Tsuchiya, T	1
Baeschlin, DK; Beswick, M; Clark, DE; Duttaroy, A; Fenton, G; Ferreira, S; Flohr, S; Gerhartz, B; Gessier, F; Hassiepen, U; Namoto, K; Ostermann, N; Sedrani, R; Sirockin, F; Sutton, JM; Trappe, J	1
Al-Deeb, OA; Al-Tamimi, AM; El-Emam, AA; Pathak, SK; Prasad, O; Sinha, L; Srivastava, R	1
Tibaldi, JM	1
Addla, D; Gurram, D; Jallapally, A; Kantevari, S; Sriram, D; Yogeeswari, P	1
Athyros, VG; Elisaf, MS; Filippatos, TD	1
Chi, J; Gu, W; Hong, J; Ning, G; Wang, B; Wang, W; Zhang, Y	1
Iwamura, T; Kainoh, M; Kawai, K; Kumagai, H; Nakaki, J; Nitta, A; Okazaki, S; Sakami, S; Sato, M; Sekiya, Y; Takahashi, T; Yagi, M	1
Marchesini, G; Melchiorri, D; Montilla, S; Pani, L; Sammarco, A; Siviero, PD; Tomino, C; Trotta, MP	1
Al-Abdullah, ES; Alanazi, AM; Almutairi, MS; El-Emam, AA; Pathak, SK; Prasad, O; Sinha, L; Srivastava, R	1
Benaim, G; de Carvalho, TM; de Souza, W; Docampo, R; Galizzi, M; Gonzalez-Pacanowska, D; Guo, RT; Hernandez-Rodriguez, V; Huang, G; Lameira, L; Li, K; Li, Q; Oldfield, E; Shang, N; Urbina, JA; Veiga-Santos, P	1
Al-Abdullah, ES; Al-Alshaikh, MA; Al-Tuwaijri, HM; El-Emam, AA; Habib, EE; Hassan, HM	1
Bhamidipati, RK; Gilibili, RR; Mullangi, R; Srinivas, NR	1
Amante, F; Cooper, MA; Dwyer, PJ; Faleiro, R; Horne-Debets, JM; Huang, JX; Karunarathne, DS; Lee, JS; Leow, CY; McCarthy, JS; Miles, JJ; Poh, CM; Rénia, L; Richard, D; Sharpe, AH; Stacey, KJ; Watkins, TS; Wykes, MN; Yarski, M	1
Jakovljević, K; Joksović, MD; Kanazir, S; Leovac, VM; Marković, V; Matić, IZ; Milošev, MZ; Mladenović, M; Perović, M; Rodić, MV; Stanojković, T; Tešić, V; Trifunović, S	1
Westhovens, R	1
Ballard, E; Chalon, S; Collins, KA; Elliott, SL; Griffin, P; Marquart, L; McCarthy, JS; Möhrle, JJ; Rückle, T	1
Georgiou, S; Plachouri, KM	1
Akakpo, S; Chalon, S; Chughlay, MF; Csermak-Renner, K; Djeriou, E; Gaur, AH; Leboulleux, D; McCarthy, J; Odedra, A; Shanks, GD; Winnips, C	1
Gyu Song, G; Ho Lee, Y	1
Aletaha, D; Baraliakos, X; Boehncke, WH; de Wit, M; Dörner, T; Dougados, M; Emery, P; Fleischmann, RM; Geissler, K; Isaacs, JD; Kerschbaumer, A; Kremer, J; Lee, EB; Maksymowych, WP; McInnes, I; Nash, P; Pope, JE; Smolen, JS; Stoffer-Marx, M; Takeuchi, T; Tam, LS; Tanaka, Y; Trauner, M; van den Bosch, F; van der Heijde, D; Voshaar, M; Westhovens, R; Winthrop, KL; Xavier, R	1
Buenrostro, JD; Du, Z; Kshirsagar, S; Li, Q; Ma, S; Meissner, TB; Strominger, JL; Tilburgs, T; Uesugi, M; Wang, F	1
Fearon, U; Flynn, K; Hanlon, MM; Marzaioli, V; O'Brien, A; Veale, DJ; Wade, SC	1
Kim, JW; Kim, SY	1

Reviews

66 review(s) available for adamantane and triazoles

Article	Year
[Dipeptidylpeptidase IV inhibitors and dual action PPAR-agonists]. Medizinische Monatsschrift fur Pharmazeuten, 2006, Volume: 29, Issue:3 Topics: Adamantane; Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Glycine; Glycoproteins; Humans; Hypoglycemic Agents; Nitriles; Oxazoles; Peroxisome Proliferator-Activated Receptors; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2006
DPP-4 inhibitors and their potential role in the management of type 2 diabetes. International journal of clinical practice, 2006, Volume: 60, Issue:11 Topics: Adamantane; Adenosine Deaminase Inhibitors; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycoproteins; Humans; Hypoglycemic Agents; Models, Animal; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2006
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet (London, England), 2006, Nov-11, Volume: 368, Issue:9548 Topics: Adamantane; Adenosine Deaminase Inhibitors; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycoproteins; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2006
Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes. Diabetes & vascular disease research, 2006, Volume: 3, Issue:3 Topics: Adamantane; Adenosine Deaminase; Adenosine Deaminase Inhibitors; Animals; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Evaluation, Preclinical; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Isoenzymes; Nitriles; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2006
Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications. Diabetes care, 2007, Volume: 30, Issue:6 Topics: Adamantane; Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycoproteins; Humans; Hypoglycemic Agents; Nitriles; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2007
[Incretin enhancers, incretin mimetics: from therapeutic concept to clinical application]. Orvosi hetilap, 2007, Apr-01, Volume: 148, Issue:13 Topics: Adamantane; Adenosine Deaminase; Adenosine Deaminase Inhibitors; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Gastric Inhibitory Polypeptide; Gastrointestinal Hormones; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Insulin Resistance; Intestinal Mucosa; Nitriles; Peptide Hormones; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2007
Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Current medical research and opinion, 2007, Volume: 23, Issue:4 Topics: Adamantane; Adenosine Deaminase Inhibitors; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucose; Glycoproteins; Homeostasis; Humans; Hypoglycemic Agents; Islets of Langerhans; Models, Biological; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2007
[New concepts in the treatment of type 2 diabetes]. Der Internist, 2007, Volume: 48, Issue:7 Topics: Adamantane; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Nitriles; Peptides; Piperidines; Pyrazines; Pyrazoles; Pyrrolidines; Rimonabant; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2007
Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA, 2007, Jul-11, Volume: 298, Issue:2 Topics: Adamantane; Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2007
Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus. Pharmacotherapy, 2007, Volume: 27, Issue:8 Topics: Adamantane; Adenosine Deaminase Inhibitors; Administration, Oral; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Delivery Systems; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2007
DPP-4 inhibitors. Best practice & research. Clinical endocrinology & metabolism, 2007, Volume: 21, Issue:4 Topics: Adamantane; Animals; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Lipid Metabolism; Metformin; Nitriles; Pioglitazone; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Substrate Specificity; Thiazolidinediones; Triazoles; Vildagliptin	2007
GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors. Current diabetes reports, 2007, Volume: 7, Issue:5 Topics: Adamantane; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Enzyme Inhibitors; Exenatide; Gastric Emptying; Glucagon-Like Peptide 1; Hypoglycemic Agents; Incretins; Islets of Langerhans; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2007
Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. The Cochrane database of systematic reviews, 2008, Apr-16, Issue:2 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Nitriles; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Vildagliptin	2008
Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes. Expert opinion on investigational drugs, 2008, Volume: 17, Issue:6 Topics: Adamantane; Body Weight; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Nausea; Nitriles; Peptides; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin; Vomiting	2008
Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes. Frontiers in bioscience : a journal and virtual library, 2008, May-01, Volume: 13 Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Humans; Hypoglycemic Agents; Incretins; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2008
Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Current opinion in clinical nutrition and metabolic care, 2008, Volume: 11, Issue:4 Topics: Adamantane; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2008
Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin. Vascular health and risk management, 2008, Volume: 4, Issue:2 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Metformin; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles; Vildagliptin	2008
From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents. Current opinion in drug discovery & development, 2008, Volume: 11, Issue:4 Topics: Adamantane; Administration, Oral; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Design; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Models, Molecular; Molecular Structure; Nitriles; Protein Conformation; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Structure-Activity Relationship; Treatment Outcome; Triazoles; Vildagliptin	2008
New treatments for type 2 diabetes--the DPP4 inhibitors. Primary care diabetes, 2007, Volume: 1, Issue:4 Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Vildagliptin	2007
DPP4 inhibitors: a new approach in diabetes treatment. Advances in therapy, 2008, Volume: 25, Issue:7 Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2008
DPP4 inhibitors for diabetes--what next? Biochemical pharmacology, 2008, Dec-15, Volume: 76, Issue:12 Topics: Adamantane; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Hypoxia; Neoplasms; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2008
Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes. Arquivos brasileiros de endocrinologia e metabologia, 2008, Volume: 52, Issue:6 Topics: Adamantane; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Fasting; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Nitriles; Peptides; Postprandial Period; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2008
[Sitagliptin. DPP-4 inhibitors as a useful extension of oral diabetes therapy?]. Deutsche medizinische Wochenschrift (1946), 2008, Volume: 133, Issue:43 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Enzyme Inhibitors; Glucagon-Like Peptide 1; Glucose; Humans; Hypoglycemic Agents; Incretins; Insulin; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2008
Dipeptidyl peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic review. Cardiology clinics, 2008, Volume: 26, Issue:4 Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2008
Incretin-based therapies in type 2 diabetes: a review of clinical results. Diabetes research and clinical practice, 2008, Dec-15, Volume: 82 Suppl 2 Topics: Adamantane; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Incretins; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2008
Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vascular health and risk management, 2008, Volume: 4, Issue:4 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Vildagliptin	2008
Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus. Mymensingh medical journal : MMJ, 2009, Volume: 18, Issue:1 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2009
DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy. Advances in therapy, 2009, Volume: 26, Issue:3 Topics: Adamantane; Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Pioglitazone; Piperidines; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Uracil	2009
Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes. Acta bio-medica : Atenei Parmensis, 2008, Volume: 79, Issue:3 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2008
Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential. Vascular health and risk management, 2008, Volume: 4, Issue:6 Topics: Adamantane; Blood Glucose; Body Weight; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Edema; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Nitriles; Pioglitazone; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Vildagliptin	2008
[The value of incretin based therapies]. Deutsche medizinische Wochenschrift (1946), 2009, Volume: 134, Issue:20 Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2009
[Incretin related agents for treatment of diabetes mellitus]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2009, Apr-10, Volume: 98, Issue:4 Topics: Adamantane; Diabetes Mellitus; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2009
Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events. Best practice & research. Clinical endocrinology & metabolism, 2009, Volume: 23, Issue:4 Topics: Adamantane; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Insulin; Metformin; Nitriles; Pioglitazone; Pyrazines; Pyrrolidines; Sensitivity and Specificity; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Vildagliptin	2009
Defining the importance of daily glycemic control and implications for type 2 diabetes management. Postgraduate medicine, 2009, Volume: 121, Issue:5 Topics: Adamantane; Blood Glucose Self-Monitoring; Circadian Rhythm; Cost of Illness; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Glycated Hemoglobin; Glycemic Index; Humans; Incretins; Pyrazines; Sitagliptin Phosphate; Treatment Failure; Triazoles	2009
DPP-4 inhibitors in clinical practice. Postgraduate medicine, 2009, Volume: 121, Issue:6 Topics: Adamantane; Administration, Oral; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2009
Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus. Cleveland Clinic journal of medicine, 2009, Volume: 76 Suppl 5 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glutaminase; Homeostasis; Humans; Hypoglycemic Agents; Incretins; Intracellular Signaling Peptides and Proteins; Peptides; Pyrazines; Signal Transduction; Sitagliptin Phosphate; Triazoles; Venoms	2009
Medicinal Chemistry of Incretin Mimetics and DPP-4 Inhibitors. ChemMedChem, 2010, Feb-01, Volume: 5, Issue:2 Topics: Adamantane; Amino Acid Sequence; Chemistry, Pharmaceutical; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Insulin-Secreting Cells; Molecular Sequence Data; Nitriles; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2010
[DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia]. Pharmazie in unserer Zeit, 2010, Volume: 39, Issue:2 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2010
[New blood glucose-lowering drugs in type 2 diabetes: a review of the literature]. Nederlands tijdschrift voor geneeskunde, 2010, Volume: 154 Topics: Adamantane; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Vildagliptin	2010
The physiologic role of incretin hormones: clinical applications. The Journal of the American Osteopathic Association, 2010, Volume: 110, Issue:3 Suppl 2 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Incretins; Piperidines; Pyrazines; Sitagliptin Phosphate; Triazoles; Uracil	2010
Managing type 2 diabetes in the primary care setting: beyond glucocentricity. The American journal of the medical sciences, 2010, Volume: 340, Issue:2 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Hypoglycemic Agents; Liraglutide; Nitriles; Obesity; Patient Compliance; Peptides; Piperidines; Precision Medicine; Primary Health Care; Pyrazines; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Triazoles; Uracil; Venoms; Vildagliptin	2010
Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes, obesity & metabolism, 2010, Volume: 12, Issue:8 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Half-Life; Humans; Hypoglycemic Agents; Male; Nitriles; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Vildagliptin	2010
A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology, 2010, Volume: 86, Issue:1 Topics: Adamantane; Adult; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin; Weight Loss	2010
Incretin physiology and its role in type 2 diabetes mellitus. The Journal of the American Osteopathic Association, 2010, Volume: 110, Issue:7 Suppl 7 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms	2010
Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health technology assessment (Winchester, England), 2010, Volume: 14, Issue:36 Topics: Adamantane; Body Weight; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Nitriles; Peptides; Pyrazines; Pyrrolidines; Quality of Life; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; State Medicine; Thiazolidinediones; Triazoles; United Kingdom; Venoms; Vildagliptin	2010
Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Clinical pharmacokinetics, 2010, Volume: 49, Issue:9 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin	2010
DPP-4 inhibitors: what may be the clinical differentiators? Diabetes research and clinical practice, 2010, Volume: 90, Issue:2 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Energy Intake; Gastric Emptying; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Intestinal Mucosa; Linagliptin; Neurons; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin	2010
Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting. The American journal of managed care, 2010, Volume: 16, Issue:7 Suppl Topics: Adamantane; Algorithms; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Evidence-Based Medicine; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Liraglutide; Managed Care Programs; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms	2010
Focus on incretin-based therapies: targeting the core defects of type 2 diabetes. Postgraduate medicine, 2011, Volume: 123, Issue:1 Topics: Adamantane; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms	2011
Incretin therapies in the management of elderly patients with type 2 diabetes mellitus. Hospital practice (1995), 2011, Volume: 39, Issue:1 Topics: Adamantane; Age Factors; Aged; Aging; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Male; Middle Aged; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Vildagliptin	2011
[Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs]. Orvosi hetilap, 2011, Sep-11, Volume: 152, Issue:37 Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Metformin; Nitriles; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Tablets; Treatment Outcome; Triazoles; Vildagliptin	2011
[Incretin-based therapy for treating patients with type 2 diabetes]. Orvosi hetilap, 2011, Nov-27, Volume: 152, Issue:48 Topics: Adamantane; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Exenatide; Gliclazide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hungary; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Metformin; Nitriles; Peptides; Pioglitazone; Purines; Pyrazines; Pyrrolidines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Venoms; Vildagliptin	2011
Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:6 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2012
Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results. Journal of clinical pharmacology, 2012, Volume: 52, Issue:10 Topics: Adamantane; Biomarkers; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Models, Biological; Nitriles; Piperidines; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Vildagliptin	2012
DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. Diabetes & metabolism, 2012, Volume: 38, Issue:2 Topics: Adamantane; Clinical Trials as Topic; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin; Weight Gain	2012
An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors. Current diabetes reviews, 2012, Volume: 8, Issue:3 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Glucagon-Like Peptide 1; Humans; Linagliptin; Male; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Vildagliptin	2012
Noninsulin glucose-lowering agents for the treatment of patients on dialysis. Nature reviews. Nephrology, 2013, Volume: 9, Issue:3 Topics: Adamantane; Biguanides; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Glucagon-Like Peptides; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Linagliptin; Meglumine; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Dialysis; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Uracil; Vildagliptin	2013
Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence? Hospital practice (1995), 2013, Volume: 41, Issue:2 Topics: Adamantane; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin	2013
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes. Postgraduate medicine, 2013, Volume: 125, Issue:3 Topics: Adamantane; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular System; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Lipids; Nitriles; Pyrazines; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Triazoles; Vildagliptin	2013
Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes. Advances in therapy, 2014, Volume: 31, Issue:3 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Linagliptin; Liraglutide; Peptides; Piperidines; Purines; Pyrazines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Weight Loss	2014
The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected]. Expert opinion on drug metabolism & toxicology, 2014, Volume: 10, Issue:6 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Linagliptin; Nitriles; Piperidines; Piperidones; Purines; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Thiazolidines; Triazoles; Uracil; Vildagliptin	2014
Clinical efficacy of new JAK inhibitors under development. Just more of the same? Rheumatology (Oxford, England), 2019, 02-01, Volume: 58, Issue:Suppl 1 Topics: Adamantane; Arthritis, Rheumatoid; Azetidines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase 1; Janus Kinase 3; Janus Kinase Inhibitors; Niacinamide; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome; Triazoles; Valine	2019
JAK inhibitors in chronic plaque psoriasis: What is known so far. Drugs of today (Barcelona, Spain : 1998), 2020, Volume: 56, Issue:2 Topics: Adamantane; Azetidines; Humans; Janus Kinase Inhibitors; Janus Kinases; Niacinamide; Nitriles; Piperidines; Prospective Studies; Psoriasis; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Triazoles	2020
Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis. Journal of clinical pharmacy and therapeutics, 2020, Volume: 45, Issue:4 Topics: Adamantane; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Bayes Theorem; Heterocyclic Compounds, 3-Ring; Humans; Niacinamide; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Randomized Controlled Trials as Topic; Sulfonamides; Triazoles	2020
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Annals of the rheumatic diseases, 2021, Volume: 80, Issue:1 Topics: Adamantane; Advisory Committees; Antirheumatic Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Azetidines; Cytokines; Drug Therapy, Combination; Europe; Heterocyclic Compounds, 3-Ring; Humans; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Niacinamide; Piperidines; Psoriasis; Purines; Pyrazoles; Pyridines; Pyrimidines; Rheumatology; Spondylarthropathies; Spondylitis, Ankylosing; Sulfonamides; Triazoles	2021
The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment. International journal of molecular sciences, 2021, Oct-20, Volume: 22, Issue:21 Topics: Adamantane; Colitis; Colitis, Ulcerative; Crohn Disease; Heterocyclic Compounds, 3-Ring; Humans; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Janus Kinases; Niacinamide; Piperidines; Pyridines; Pyrimidines; Pyrroles; Triazoles	2021

Trials

10 trial(s) available for adamantane and triazoles

Article	Year
Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes/metabolism research and reviews, 2010, Volume: 26, Issue:7 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2010
The metabolic syndrome influences the response to incretin-based therapies. Acta diabetologica, 2011, Volume: 48, Issue:3 Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Male; Metabolic Syndrome; Middle Aged; Nitriles; Peptides; Prognosis; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Vildagliptin	2011
Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results. Journal of clinical pharmacology, 2012, Volume: 52, Issue:10 Topics: Adamantane; Biomarkers; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Models, Biological; Nitriles; Piperidines; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Vildagliptin	2012
Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes care, 2012, Volume: 35, Issue:10 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Inflammation; Interleukin-18; Interleukin-6; Male; Metformin; Middle Aged; Nitriles; Oxidative Stress; Postprandial Period; Prospective Studies; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2012
Add-on therapies to metformin in type 2 diabetes: what modulates the respective decrements in postprandial and basal glucose? Diabetes technology & therapeutics, 2012, Volume: 14, Issue:10 Topics: Adamantane; Adult; Aged; Analysis of Variance; Area Under Curve; Basal Metabolism; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Postprandial Period; Pyrazines; Pyrrolidines; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Vildagliptin	2012
Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study. Diabetes & metabolism, 2012, Volume: 38, Issue:4 Topics: Adamantane; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; France; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pilot Projects; Prospective Studies; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Vildagliptin; Young Adult	2012
Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study). Cardiovascular diabetology, 2012, Aug-06, Volume: 11 Topics: Adamantane; Adult; Aged; Biomarkers; Blood Glucose; C-Peptide; Cross-Over Studies; Deoxyglucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Female; Glycated Hemoglobin; Glycated Serum Albumin; Glycation End Products, Advanced; Humans; Japan; Male; Middle Aged; Monitoring, Ambulatory; Natriuretic Peptide, Brain; Nitriles; Pilot Projects; Plasminogen Activator Inhibitor 1; Postprandial Period; Predictive Value of Tests; Pyrazines; Pyrrolidines; Serum Albumin; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles; Vildagliptin	2012
Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. Atherosclerosis, 2013, Volume: 227, Issue:2 Topics: Adamantane; Atherosclerosis; Blood Glucose; Carotid Arteries; Carotid Artery Diseases; Carotid Intima-Media Thickness; Cytokines; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Inflammation; Nitriles; Oxidative Stress; Prospective Studies; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Tyrosine; Vildagliptin	2013
Different effects of two dipeptidyl peptidase-4 inhibitors and glimepiride on β-cell function in a newly designed two-step hyperglycemic clamp. Journal of diabetes, 2015, Volume: 7, Issue:2 Topics: Adamantane; Adult; Blood Glucose; Cross-Over Studies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Follow-Up Studies; Glucose Clamp Technique; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Prognosis; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles	2015
A Single-Dose Combination Study with the Experimental Antimalarials Artefenomel and DSM265 To Determine Safety and Antimalarial Activity against Blood-Stage Plasmodium falciparum in Healthy Volunteers. Antimicrobial agents and chemotherapy, 2019, 12-20, Volume: 64, Issue:1 Topics: Adamantane; Administration, Oral; Adult; Antimalarials; Drug Combinations; Female; Healthy Volunteers; Humans; Malaria, Falciparum; Male; Middle Aged; Parasitemia; Peroxides; Plasmodium falciparum; Pyrimidines; Triazoles; Young Adult	2019

Other Studies

65 other study(ies) available for adamantane and triazoles

Article	Year
[Adamantane derivatives of benzotriazole (author's transl)]. Archiv der Pharmazie, 1976, Volume: 309, Issue:4 Topics: Adamantane; Triazoles	1976
Synthesis and anti-inflammatory and analgesic activity of some 3-(1-adamantyl)-4-substituted-5-mercapto-1,2,4-triazoles. Arzneimittel-Forschung, 1991, Volume: 41, Issue:12 Topics: Adamantane; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Dose-Response Relationship, Drug; Edema; Lethal Dose 50; Magnetic Resonance Spectroscopy; Male; Mice; Pain Measurement; Rats; Sulfhydryl Compounds; Triazoles	1991
Effects of the adenosine A1-receptor antagonist on defecation, small intestinal propulsion and gastric emptying in rats. Japanese journal of pharmacology, 1995, Volume: 68, Issue:1 Topics: Adamantane; Animals; Bisacodyl; Defecation; Gastric Emptying; Gastrointestinal Motility; Imidazoles; Intestine, Small; Male; Purinergic P1 Receptor Antagonists; Pyrazines; Quinazolines; Rats; Rats, Sprague-Dawley; Triazoles; Xanthines	1995
Synthesis and antiviral activity evaluation of some new 6-substituted 3-(1-adamantyl)-1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles. Farmaco (Societa chimica italiana : 1989), 2002, Volume: 57, Issue:3 Topics: Adamantane; Animals; Anti-HIV Agents; Antiviral Agents; Chlorocebus aethiops; HeLa Cells; HIV-1; HIV-2; Humans; Magnetic Resonance Spectroscopy; Microbial Sensitivity Tests; Molecular Structure; T-Lymphocytes; Thiadiazoles; Triazoles; Vero Cells; Zidovudine	2002
Adamantyl triazoles as selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1. Bioorganic & medicinal chemistry letters, 2005, Oct-01, Volume: 15, Issue:19 Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adamantane; Animals; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Metabolic Syndrome; Mice; Pharmacokinetics; Structure-Activity Relationship; Triazoles	2005
American Diabetes Association - 65th Scientific Sessions. DDP-IV inhibitors. IDrugs : the investigational drugs journal, 2005, Volume: 8, Issue:8 Topics: Adamantane; Animals; Dipeptidyl Peptidase 4; Glucagon; Glucagon-Like Peptide 1; Humans; Islets of Langerhans; Nitriles; Peptide Fragments; Protease Inhibitors; Protein Precursors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin; Xanthines	2005
11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. The Journal of experimental medicine, 2005, Aug-15, Volume: 202, Issue:4 Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adamantane; Animals; Aorta; Arteriosclerosis; Azepines; Blood Glucose; Cortisone; Diet, Atherogenic; Disease Models, Animal; Enzyme Activation; Enzyme Inhibitors; Fatty Acids; Hydrocortisone; Insulin; Insulin Resistance; Male; Mice; Mice, Inbred ICR; Mice, Knockout; Syndrome; Triazoles; Triglycerides	2005
Regioselective hydroxylation of adamantane by Streptomyces griseoplanus cells. Applied microbiology and biotechnology, 2006, Volume: 71, Issue:4 Topics: Adamantane; Alcohols; Chromatography, Gas; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Hydroxylation; Magnetic Resonance Spectroscopy; Mass Spectrometry; Streptomyces; Triazoles; Vitamin K 3	2006
American Diabetes Association--66th scientific sessions. 9-13 June 2006, Washington, DC, USA. IDrugs : the investigational drugs journal, 2006, Volume: 9, Issue:8 Topics: Adamantane; Clinical Trials as Topic; Glucagon-Like Peptide 1; Humans; Liraglutide; Nitriles; Peripheral Vascular Diseases; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2006
C-glycoside clustering on calix[4]arene, adamantane, and benzene scaffolds through 1,2,3-triazole linkers. The Journal of organic chemistry, 2006, Sep-29, Volume: 71, Issue:20 Topics: Adamantane; Alkynes; Azides; Benzene; Calixarenes; Combinatorial Chemistry Techniques; Cross-Linking Reagents; Glycosides; Monosaccharides; Phenols; Triazoles	2006
Oral agents for type 2 diabetes reduce HbA1c, are weight neutral. Geriatrics, 2006, Volume: 61, Issue:9 Topics: Adamantane; Administration, Oral; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2006
New treatments for diabetes. The New England journal of medicine, 2007, May-24, Volume: 356, Issue:21 Topics: Adamantane; Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glipizide; Glycated Hemoglobin; Glycoproteins; Humans; Hypoglycemic Agents; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Vildagliptin	2007
[Glucagon-like peptide-1 (GLP-1), new target for the treatment of type 2 diabetes]. Revue medicale de Liege, 2007, Volume: 62, Issue:4 Topics: Adamantane; Animals; Appetite; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2007
2-amino-1,3-thiazol-4(5H)-ones as potent and selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: enzyme-ligand co-crystal structure and demonstration of pharmacodynamic effects in C57Bl/6 mice. Journal of medicinal chemistry, 2008, May-22, Volume: 51, Issue:10 Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adamantane; Adipose Tissue; Animals; Cortisone; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Humans; Hydrocortisone; Hypoglycemic Agents; Ligands; Liver; Male; Mice; Mice, Inbred C57BL; Models, Molecular; Molecular Structure; Rats; Stereoisomerism; Structure-Activity Relationship; Thiazoles; Triazoles	2008
Three new drugs for type 2 diabetes. Drug and therapeutics bulletin, 2008, Volume: 46, Issue:7 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Humans; Hypoglycemic Agents; Incretins; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Vildagliptin	2008
[Future therapeutic options and their indications: transplantation and the possibilities of regenerative therapy for diabetes type 1]. MMW Fortschritte der Medizin, 2008, Oct-30, Volume: 150, Issue:44 Topics: Adamantane; Animals; Diabetes Mellitus, Type 1; Exenatide; Humans; Insulin-Secreting Cells; Islets of Langerhans; Islets of Langerhans Transplantation; Mice; Nitriles; Peptides; Pyrazines; Pyrrolidines; Regeneration; Sitagliptin Phosphate; Stem Cell Transplantation; Transplantation, Heterologous; Triazoles; Venoms; Vildagliptin	2008
Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Current drug targets, 2009, Volume: 10, Issue:1 Topics: Adamantane; Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drugs, Investigational; Humans; Hypoglycemic Agents; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Substrate Specificity; Treatment Outcome; Triazoles; Vildagliptin	2009
Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best practice & research. Clinical endocrinology & metabolism, 2009, Volume: 23, Issue:4 Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2009
Call for comparative effectiveness research: lowering A1c with sitagliptin, saxagliptin, or cinnamon. Journal of managed care pharmacy : JMCP, 2009, Volume: 15, Issue:8 Topics: Adamantane; Cinnamomum zeylanicum; Comparative Effectiveness Research; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles	2009
[New hypoglycemic agents in type 2 diabetes]. La Revue du praticien, 2010, Apr-20, Volume: 60, Issue:4 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2010
Choosing among the incretin agents and why it matters. The Journal of family practice, 2010, Volume: 59, Issue:5 Suppl Topics: Adamantane; Blood Pressure; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Lipids; Liraglutide; Male; Middle Aged; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms; Weight Loss	2010
Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies. The Journal of family practice, 2010, Volume: 59, Issue:9 Suppl 1 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms	2010
Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies. The Journal of family practice, 2010, Volume: 59, Issue:9 Suppl 1 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Risk; Sitagliptin Phosphate; Triazoles; Venoms; Weight Loss	2010
Distinguishing among incretin-based therapies. Patient education and self-management. The Journal of family practice, 2010, Volume: 59, Issue:9 Suppl 1 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Patient Education as Topic; Peptides; Pyrazines; Receptors, Glucagon; Self Care; Sitagliptin Phosphate; Triazoles; Venoms	2010
Distinguishing among incretin-based therapies. Introduction. The Journal of family practice, 2010, Volume: 59, Issue:9 Suppl 1 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Exenatide; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Insulin-Secreting Cells; Liraglutide; Metformin; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms	2010
Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies. The Journal of family practice, 2010, Volume: 59, Issue:9 Suppl 1 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Time Factors; Triazoles; Venoms	2010
An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development. Contemporary clinical trials, 2011, Volume: 32, Issue:3 Topics: Adamantane; Allylamine; Cardiovascular Diseases; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Investigational New Drug Application; Liraglutide; Nitriles; Peptides; Piperidines; Practice Guidelines as Topic; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Time Factors; Triazoles; United States; United States Food and Drug Administration; Uracil; Venoms; Vildagliptin	2011
Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials. Clinical drug investigation, 2011, Volume: 31, Issue:9 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Female; Glycated Hemoglobin; Humans; Japan; Male; Middle Aged; Nitriles; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Vildagliptin	2011
Target-mediated metabolism and target-mediated drug disposition of the DPPIV inhibitor AMG 222. Xenobiotica; the fate of foreign compounds in biological systems, 2011, Volume: 41, Issue:11 Topics: Adamantane; Amides; Blood Proteins; Carbon Radioisotopes; Chromatography, High Pressure Liquid; Dibenzocycloheptenes; Dipeptidyl-Peptidase IV Inhibitors; Drug Delivery Systems; Humans; Inhibitory Concentration 50; Kinetics; Nitriles; Protein Binding; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Tetrazoles; Time Factors; Triazoles; Ultracentrifugation; Vildagliptin	2011
Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor. BMC pharmacology, 2012, Apr-04, Volume: 12 Topics: Adamantane; Algorithms; Animals; Artifacts; Cloning, Molecular; Dipeptidases; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Indicators and Reagents; Kinetics; Macaca fascicularis; Nitriles; Protein Binding; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Species Specificity; Triazoles; Vildagliptin	2012
Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β-cell mass in a streptozotocin-induced mouse model of type 2 diabetes. Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:10 Topics: Adamantane; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Dipeptides; Drinking; Eating; Glucose Tolerance Test; Glycated Hemoglobin; Hypoglycemic Agents; Immunohistochemistry; Insulin-Secreting Cells; Male; Mice; Mice, Inbred C57BL; Pyrazines; Sitagliptin Phosphate; Triazoles	2012
[Therapeutic use and adverse events of incretin-related drugs]. Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 3 Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Venoms; Vildagliptin	2012
A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations. European journal of pharmacology, 2012, Dec-05, Volume: 696, Issue:1-3 Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Hyperglycemia; Hypertriglyceridemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Nitriles; Pyrazines; Pyrazoles; Pyrrolidines; Rats; Rats, Wistar; Rats, Zucker; Sitagliptin Phosphate; Thiazolidines; Triazoles; Vildagliptin	2012
Adenosine A2A receptor modulates vascular response in soluble epoxide hydrolase-null mice through CYP-epoxygenases and PPARγ. American journal of physiology. Regulatory, integrative and comparative physiology, 2013, Jan-01, Volume: 304, Issue:1 Topics: 8,11,14-Eicosatrienoic Acid; Adamantane; Adenosine; Adenosine A2 Receptor Agonists; Adenosine A2 Receptor Antagonists; Adenosine-5'-(N-ethylcarboxamide); Animals; Benzamides; Benzoates; Butyrates; Enzyme Inhibitors; Epoxide Hydrolases; Female; Gene Silencing; Lauric Acids; Male; Mice; NG-Nitroarginine Methyl Ester; Oxygenases; Phenethylamines; Phenylurea Compounds; PPAR gamma; Pyridines; Pyrimidines; Receptor, Adenosine A2A; Triazines; Triazoles; Urea; Vasodilation; Vasodilator Agents	2013
Comment on: Rizzo et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012;35:2076-2082. Diabetes care, 2013, Volume: 36, Issue:1 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male; Nitriles; Pyrazines; Pyrrolidines; Triazoles	2013
Response to Comment on: Rizzo et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012;35:2076-2082. Diabetes care, 2013, Volume: 36, Issue:1 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male; Nitriles; Pyrazines; Pyrrolidines; Triazoles	2013
Lipophilic adamantyl- or deferasirox-based conjugates of desferrioxamine B have enhanced neuroprotective capacity: implications for Parkinson disease. Free radical biology & medicine, 2013, Volume: 60 Topics: Adamantane; Animals; Astrocytes; Benzoates; Cells, Cultured; Deferasirox; Deferoxamine; Dopaminergic Neurons; Humans; Hydrogen Peroxide; Iron Chelating Agents; Mice; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Permeability; Substantia Nigra; Triazoles	2013
DPP4 inhibitor-induced polyarthritis: a report of three cases. Rheumatology international, 2014, Volume: 34, Issue:2 Topics: Adamantane; Arthritis; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Pyrazines; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Triazoles; Vildagliptin	2014
Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin-resistant rats. British journal of pharmacology, 2013, Volume: 169, Issue:5 Topics: Adamantane; Animals; Blood Glucose; Blood Pressure; Body Weight; Cardiotonic Agents; Cholesterol; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Heart; Heart Rate; Insulin; Insulin Resistance; Male; Malondialdehyde; Membrane Potential, Mitochondrial; Mitochondria, Heart; Nitriles; Obesity; Oxidative Stress; Pyrazines; Pyrrolidines; Rats, Wistar; Reactive Oxygen Species; Sitagliptin Phosphate; Triazoles; Vildagliptin	2013
A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site. Biochemical and biophysical research communications, 2013, May-03, Volume: 434, Issue:2 Topics: Adamantane; Catalytic Domain; Crystallography, X-Ray; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Humans; Multiprotein Complexes; Nitriles; Oligopeptides; Piperidines; Protein Binding; Protein Interaction Mapping; Pyrazines; Pyrazoles; Pyrrolidines; Serine; Sitagliptin Phosphate; Structure-Activity Relationship; Thiazolidines; Triazoles; Uracil; Vildagliptin; X-Ray Diffraction	2013
DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats. The Journal of endocrinology, 2013, Volume: 218, Issue:1 Topics: Adamantane; Animals; Behavior, Animal; Brain; Cognition Disorders; Diabetes Mellitus, Type 2; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Hippocampus; Insulin Resistance; Male; Maze Learning; Memory; Memory Disorders; Mitochondria; Nitriles; Obesity; Oxidative Stress; Pyrazines; Pyrrolidines; Rats; Rats, Wistar; Sitagliptin Phosphate; Triazoles; Vildagliptin	2013
Reports of pancreatitis are 20-30 times more likely with GLP-1 drugs, analysis finds. BMJ (Clinical research ed.), 2013, Apr-23, Volume: 346 Topics: Adamantane; Diabetes Mellitus; Dipeptides; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Linagliptin; Pancreatitis; Purines; Pyrazines; Quinazolines; Sitagliptin Phosphate; Triazoles; United States	2013
Antidiabetic gliptins in combination with G-CSF enhances myocardial function and survival after acute myocardial infarction. International journal of cardiology, 2013, Oct-09, Volume: 168, Issue:4 Topics: Adamantane; Animals; Cell Survival; Drug Therapy, Combination; Granulocyte Colony-Stimulating Factor; Heart; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2013
Comment on: Rizzo et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012;35:2076-2082. Diabetes care, 2013, Volume: 36, Issue:6 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male; Nitriles; Pyrazines; Pyrrolidines; Triazoles	2013
Clinical characteristics of the responders to dipeptidyl peptidase-4 inhibitors in Korean subjects with type 2 diabetes. Journal of Korean medical science, 2013, Volume: 28, Issue:6 Topics: Adamantane; Blood Glucose; Body Mass Index; C-Peptide; Creatinine; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Insulin Resistance; Male; Middle Aged; Multivariate Analysis; Nitriles; Pyrazines; Pyrrolidines; Retrospective Studies; Sitagliptin Phosphate; Triazoles; Vildagliptin	2013
Synthesis and antimicrobial activity of novel 5-(1-adamantyl)-2-aminomethyl-4-substituted-1,2,4-triazoline-3-thiones. European journal of medicinal chemistry, 2013, Volume: 68 Topics: Adamantane; Anti-Infective Agents; Bacteria; Candida albicans; Mannich Bases; Microbial Sensitivity Tests; Thiones; Triazoles	2013
Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner. Cardiovascular diabetology, 2013, Oct-22, Volume: 12 Topics: Adamantane; Animals; Cyclic AMP-Dependent Protein Kinases; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Heart; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Nitriles; Pyrazines; Pyrrolidines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Glucagon; Severity of Illness Index; Signal Transduction; Sitagliptin Phosphate; Triazoles; Vildagliptin	2013
The dipeptidylpeptidase-IV inhibitors sitagliptin, vildagliptin and saxagliptin do not impair innate and adaptive immune responses. Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:6 Topics: Adamantane; Adaptive Immunity; Animals; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Immunity, Innate; Mice; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; T-Lymphocytes; Triazoles; Vildagliptin	2014
Pharmacoeconomic analysis of DPP-4 inhibitors. Die Pharmazie, 2013, Volume: 68, Issue:11 Topics: Adamantane; Clinical Trials as Topic; Cohort Studies; Cost-Benefit Analysis; Costs and Cost Analysis; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Nitriles; Piperidines; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin	2013
Discovery of C-(1-aryl-cyclohexyl)-methylamines as selective, orally available inhibitors of dipeptidyl peptidase IV. Bioorganic & medicinal chemistry letters, 2014, Feb-01, Volume: 24, Issue:3 Topics: Adamantane; Administration, Oral; Animals; Caco-2 Cells; Crystallography, X-Ray; Cyclization; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Discovery; Enzyme Activation; Humans; Inhibitory Concentration 50; Methylamines; Molecular Structure; Nitriles; Pyrazines; Pyrrolidines; Rats; Sitagliptin Phosphate; Triazoles; Vildagliptin	2014
Structural and spectroscopic characterization of a novel potential anti-inflammatory agent 3-(adamantan-1-yl)-4-ethyl-1H-1,2,4-triazole-5(4H)thione by first principle calculations. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2014, Apr-24, Volume: 124 Topics: Adamantane; Anti-Inflammatory Agents; Dimerization; Electricity; Electrons; Hydrogen Bonding; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Conformation; Proton Magnetic Resonance Spectroscopy; Quantum Theory; Spectrophotometry, Ultraviolet; Spectrum Analysis, Raman; Static Electricity; Thermodynamics; Triazoles; Vibration	2014
Design, synthesis and evaluation of 1,2,3-triazole-adamantylacetamide hybrids as potent inhibitors of Mycobacterium tuberculosis. Bioorganic & medicinal chemistry letters, 2014, Apr-15, Volume: 24, Issue:8 Topics: Acetamides; Adamantane; Antitubercular Agents; Click Chemistry; Drug Design; HEK293 Cells; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Structure-Activity Relationship; Triazoles	2014
HIS-388, a novel orally active and long-acting 11β-hydroxysteroid dehydrogenase type 1 inhibitor, ameliorates insulin sensitivity and glucose intolerance in diet-induced obesity and nongenetic type 2 diabetic murine models. The Journal of pharmacology and experimental therapeutics, 2014, Volume: 351, Issue:1 Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adamantane; Administration, Oral; Animals; Azepines; Carbenoxolone; Diabetes Mellitus, Experimental; Enzyme Inhibitors; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Microsomes, Liver; Obesity; Pioglitazone; Thiazolidinediones; Triazoles	2014
Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2014, Volume: 24, Issue:12 Topics: Adamantane; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Utilization; Drug-Related Side Effects and Adverse Reactions; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Italy; Male; Metformin; Middle Aged; Monitoring, Physiologic; Nitriles; Peptides; Pyrazines; Pyrrolidines; Registries; Sex Factors; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2014
[Dipeptidylpeptidase-4 (DPP-4) inhibitor sitagliptin. Cardiovascular safety in type 2 diabetics]. MMW Fortschritte der Medizin, 2014, Jul-24, Volume: 156, Issue:13 Topics: Adamantane; Adult; Aged; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Middle Aged; Nitriles; Pyrazines; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Triazoles; Vildagliptin	2014
FT-IR and FT-Raman spectroscopic signatures, vibrational assignments, NBO, NLO analysis and molecular docking study of 2-{[5-(adamantan-1-yl)-4-methyl-4H-1,2,4-triazol-3-yl]sulfanyl}-N,N-dimethylethanamine. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2015, Apr-05, Volume: 140 Topics: Adamantane; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Molecular Docking Simulation; Quantum Theory; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis, Raman; Triazoles	2015
SQ109, a new drug lead for Chagas disease. Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:4 Topics: Adamantane; Animals; Chagas Disease; Ethylenediamines; Hemolysis; Humans; In Vitro Techniques; LLC-PK1 Cells; Membrane Potential, Mitochondrial; Squalene; Sterols; Swine; Triazoles; Trypanocidal Agents; Trypanosoma cruzi	2015
Gliptins: bullous pemphigoid. Prescrire international, 2015, Volume: 24, Issue:158 Topics: Adamantane; Aged; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Male; Nitriles; Pemphigoid, Bullous; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2015
Synthesis, Antimicrobial and Hypoglycemic Activities of Novel N-(1-Adamantyl)carbothioamide Derivatives. Molecules (Basel, Switzerland), 2015, May-06, Volume: 20, Issue:5 Topics: Adamantane; Animals; Anti-Bacterial Agents; Candida albicans; Diabetes Mellitus, Experimental; Gram-Negative Bacteria; Gram-Positive Bacteria; Hydrazines; Hypoglycemic Agents; Isothiocyanates; Male; Microbial Sensitivity Tests; Rats; Rats, Sprague-Dawley; Triazoles	2015
Retrospective and Prospective Human Intravenous and Oral Pharmacokinetic Projection of Dipeptidyl peptidase-IV Inhibitors Using Simple Allometric Principles - Case Studies of ABT-279, ABT-341, Alogliptin, Carmegliptin, Sitagliptin and Vildagliptin. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 2015, Volume: 18, Issue:3 Topics: Adamantane; Administration, Intravenous; Administration, Oral; Animals; Biphenyl Compounds; Dipeptidyl-Peptidase IV Inhibitors; Dogs; Haplorhini; Humans; Nitriles; Piperidines; Prospective Studies; Pyridines; Pyrrolidines; Quinolizines; Rats; Retrospective Studies; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin	2015
Programmed Death-1 Ligand 2-Mediated Regulation of the PD-L1 to PD-1 Axis Is Essential for Establishing CD4(+) T Cell Immunity. Immunity, 2016, 08-16, Volume: 45, Issue:2 Topics: Adamantane; Adult; Animals; Antimalarials; B7-H1 Antigen; CD4-Positive T-Lymphocytes; Cells, Cultured; Clinical Trials as Topic; Dendritic Cells; Female; Humans; Immunity, Cellular; Lymphocyte Activation; Malaria, Falciparum; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; Parasitemia; Peroxides; Plasmodium falciparum; Programmed Cell Death 1 Ligand 2 Protein; Programmed Cell Death 1 Receptor; Pyrimidines; Triazoles; Young Adult	2016
Mannich bases of 1,2,4-triazole-3-thione containing adamantane moiety: Synthesis, preliminary anticancer evaluation, and molecular modeling studies. Chemical biology & drug design, 2017, Volume: 89, Issue:6 Topics: Adamantane; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Fibroblasts; Humans; Inhibitory Concentration 50; Mannich Bases; Molecular Docking Simulation; Molecular Structure; Thiones; Triazoles	2017
Liver Enzyme Elevations in The American journal of tropical medicine and hygiene, 2020, Volume: 103, Issue:1 Topics: Acrylamides; Adamantane; Adult; Alanine Transaminase; Aminopyridines; Aminoquinolines; Antimalarials; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Erythrocyte Transfusion; Erythrocytes; Female; Ferrous Compounds; Healthy Volunteers; Heterocyclic Compounds, 4 or More Rings; Humans; Indoles; Isoquinolines; Malaria, Falciparum; Male; Metallocenes; Parasitemia; Peroxides; Piperazines; Plasmodium falciparum; Primaquine; Pyrimidines; Quinolines; Spiro Compounds; Sulfones; Triazoles; Young Adult	2020
ELF3 activated by a superenhancer and an autoregulatory feedback loop is required for high-level HLA-C expression on extravillous trophoblasts. Proceedings of the National Academy of Sciences of the United States of America, 2021, 03-02, Volume: 118, Issue:9 Topics: Abortion, Legal; Adamantane; Azepines; Cell Line; DNA-Binding Proteins; Enhancer Elements, Genetic; Feedback, Physiological; Female; Gene Expression Regulation, Developmental; HLA-B Antigens; HLA-C Antigens; Humans; Immunity, Maternally-Acquired; Indoles; Mediator Complex; Mediator Complex Subunit 1; Pregnancy; Pregnancy Trimester, First; Primary Cell Culture; Promoter Regions, Genetic; Protein Binding; Proto-Oncogene Proteins c-ets; Regulatory Factor X Transcription Factors; RNA, Small Interfering; Signal Transduction; Transcription Factors; Triazoles; Trophoblasts	2021
Targeting JAK-STAT Signalling Alters PsA Synovial Fibroblast Pro-Inflammatory and Metabolic Function. Frontiers in immunology, 2021, Volume: 12 Topics: Adamantane; Adult; Aged; Arthritis, Psoriatic; Azetidines; Cells, Cultured; Female; Fibroblasts; Heterocyclic Compounds, 3-Ring; Humans; Inflammation; Janus Kinase Inhibitors; Janus Kinases; Male; Middle Aged; Niacinamide; Purines; Pyrazoles; Pyridines; Signal Transduction; STAT Transcription Factors; Sulfonamides; Synovial Membrane; Triazoles	2021